Viread took a step faster on the drug price reduction
‘Viread(generic name: tenofovir),’ a chronic type B hepatitis treatment, will took a step faster than ‘Baraclude(generic name: entecavir),’ which will face patent expiration on the coming October, on the drug price reduction.
According to the pharmaceutical industry, ceiling price of the Viread’...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
